CANCER INHIBITION;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG DESIGN;
DRUG MARKETING;
DRUG RESEARCH;
DRUG TARGETING;
EDITORIAL;
ENZYME INHIBITION;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION;
HUMAN;
LUNG CARCINOGENESIS;
LUNG NON SMALL CELL CANCER;
MOLECULAR MECHANICS;
PREDICTION;
PRIORITY JOURNAL;
TREATMENT INDICATION;
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
Mendehlson J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis
Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-2174.
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study
Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-286.
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay
Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006; 1: 19.
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice
Parulekar WR, Eiaenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 2004; 96: 990-997.
Design issues of randomized phase II trials and a proposal for phase II screening trials
Rubinstein LV, Korn EL, Friedlin B et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005; 23: 7199-7206.
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Jiang W, Friedlin B, Simon R. Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007; 99: 1036-1043.
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
Saltz LB, Meropol N, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
Van Cutsem E et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO 2007; (Abstr 4000).
